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element for osteoporosis
Manuel Scimeca1,2,10, Antonietta Salustri3,10, Elena Bonanno1,10, Daniela Nardozi1, Cecilia Rao4, Eleonora Piccirilli4, Maurizio Feola4,
Virginia Tancredi5, Annamaria Rinaldi5, Giovanni Iolascon6, Augusto Orlandi3, Elena Gasbarra4, Nicola Maffulli7,8, Maria Luisa Brandi9
and Umberto Tarantino*,4
Pentraxin 3 (PTX3) is a multifunctional glycoprotein regulating inflammatory response, cell proliferation and migration and
deposition and remodelling of the extracellular matrix by a variety of cells. In this study, we investigated the possible role of PTX3 in
bone homeostasis. To this end, we compared the expression and function of PTX3 in human osteoblasts of osteoporotic,
osteoarthritic patients and young subjects not affected by bone diseases. Immunohistochemical analysis performed on bone head
biopsies showed a close association between bone health and the number of osteoblasts expressing PTX3. Noteworthy, the
proportion of PTX3-positive osteoblasts resulted to be significantly lower in osteoporotic patients compared with both young
patients and osteoarthritic patients of the same age. Ex vivo culture of osteoblasts isolated from the three groups of patients
confirmed in vivo observation. Specifically, we observed rare runt-related transcription factor 2 (RUNX2) immunopositive
osteoblasts expressing PTX3 in cell cultures derived from osteoporotic patients and western blotting analysis showed 80%
reduction of PTX3 in the corresponding culture extracts compared with young and osteoarthritic patients. The treatment of human
osteoblast primary cultures derived from young patients with anti-PTX3 antibody dramatically affected osteoblast behaviour.
Indeed, they lost the morphological and molecular features typical of mature osteoblasts, acquiring fibroblast-like shape and
highly decreasing nuclear factor kappa-B ligand (RANKL) and RUNX2 expression. Also, the inhibition of PTX3 negatively affected
osteoblast proliferation and their ability to form cell clusters and microhydroxyapatite crystals. Altogether, these results suggest a
central role of PTX3 in bone homeostasis showing its involvement in osteoblast proliferation, differentiation and function.
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After reaching peak bone mass in the third or fourth decade in
life, the bone density begins to decline.1,2 This process
accelerates with advancing age resulting in a progressive loss
of bone solidness.1 Osteoporosis, the most common metabolic
bone disease of the elderly, is characterized by a decreased
bone strength that significantly increases the risk of fractures.3,4
Indeed, osteoporosis-related fractures are one of the major
problems in the elderly population, leading to a significant
increase in patient morbidity and consequently in health-care
service costs.5,6 From cellular point of view, bone of osteoporotic
(OP) patients exhibit an imbalance between the osteoblast and
osteoclast activity with the consequent constant decline of bone
quality in term of bone matrix composition, structural integrity of
each hierarchical length scale (i.e., osteon size and distribution)
and microdamage accumulation.7,8 Advances in knowledge of
local and systemic factors regulating matrix remodelling as well
as the identification of new markers of osteoblastogenesis and
osteoclastogenesis are needed for the design of more effective
therapies.
Pentraxin 3 (PTX3) is the prototypic long pentraxin first
identified in the early 1990s.9 Conversely to the short
pentraxin C-reactive protein (CRP) and serum amyloid P
component (SAP), which are produced primarily in the liver in
response to IL-6,10 PTX3 is released by peripheral blood
leukocytes and myeloid dendritic cells in response to primary
pro-inflammatory stimuli by acting as a non-redundant
component of the humoral arm of innate immunity and as an
essential player in tuning inflammation.11 PTX3 is also
produced by several stimuli in different cell types, such as
vascular endothelial cells, smooth muscle cells, fibroblasts,
adipocytes, chondrocytes, mesangial and epithelial and
mesenchymal stromal cells.12 Themain structural determinant
of the long pentraxins is the presence of an amino-terminal
domain, which is missing in CRP or SAP, coupled to the
C-terminal pentraxin domain.13 In agreement with the local
production and a domain with unique sequence, in addition to
its involvement in immunoregulation, PTX3 has been impli-
cated in various other biological processes in physiological
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and pathological conditions. PTX3 has been found to bind and
sequester fibroblast growth factor 2 (FGF2) via its N-terminal
extension and to suppress in vitro FGF-dependent prolifera-
tion of endothelial and smooth muscle cells and in vivo tissue
neovascularization.14,15 In addition, several lines of evidence
have also established a prominent role of PTX3 in extracellular
matrix composition and organization. It was recently demon-
strated that PTX3 regulates the injury-induced thrombotic
response16 and promotes wound healing by favouring timely
fibrinolysis.12 PTX3 expression is also induced by hormones
and local factors in the ovary where it has an essential role for
assembling hyaluronan17 in a matrix suitable for oocyte
fertilization.18,19 Few and conflicting data are available to date
concerning a possible role of PTX3 in bone metabolism. It has
been reported that PTX3 induces the expression of receptor
activator of nuclear factor kappa-B ligand (RANKL) by human
osteoblasts thereby promoting osteoclastogenesis in an
in vitro culture system.20 On the other hand, preliminary data
by Kelava et al.21 investigated the relationship between PTX3
expression and bone histomorphometry parameters in mice
deficient for the PTX3 gene demonstrating that PTX3 null mice
had lower bonemass than theirWT littermates, implying PTX3
involvement in bone formation.
Based on these evidence, we investigated the possible role
of PTX3 in the alteration of bone remodelling that occurs in OP
patients. To this end, the expression and function of PTX3 in
human osteoblasts of OP patients were compared with those
from patients affected by osteoarthritis (OA), that is, of
comparable old age but experiencing bone alterations not
necessarily linked to bone density loss, and with those from
young subjects not affected by bone diseases (CTRL).
Analyses were made in both in vivo and in vitro systems.
Results
Clinical evaluation. The OP group included 25 patients with
fragility hip fracture, T-score ≤− 2.5 S.D. and Kellgren−
Lawrence (K–L) score from 0 to 1. The OA group included 25
patients with radiographic evidence of hip OA with a K–L
score 3 or 4 and T-score ≥−2.5 S.D. (Table 1). CTRL
patients were characterized by a T-score ≥− 1.0 S.D. and
K–L score from 0 to 1. In addition, OA and OP patients
displayed homogenous values of hematochemical exams of
both bone and kidney metabolism (Table 1).
Histomorphometrical analysis. In order to characterize the
patients, conventional bone morphometric parameters, such
as bone volume (BV/TV), trabecular thickness (Tb.Th) and
trabecular separation (Tb.S), were analysed in haematoxylin
and eosin (H&E) sections by The BioQuant Osteo software
(Figures 1a–f). We detected a significant difference
among the patient groups for each considered parameter
(P= 0.0001). For what concerns BV/TV, Mann–
Whitney testing showed a significantly lower mean value in
OP patients compared with OA and CTRL patients
(OP 0.14± 0.03 mm2; OA 0.28±0.06 mm2; CTRL
0.57±0.09 mm2; OP versus OA P= 0.0076; OP versus
CTRL Po0.0001, OA versus CTRL P=0.0031; Figure 1d).
Similarly, the mean value of Tb.Th was significantly lower in
OP compared with OA and CTRL groups (OP
0.13±0.01 mm; OA 0.23±0.02 mm; CTRL 0.45±0.03 mm;
OP versus OA P=0.0013; OP versus CTRL Po0.0001; OA
versus CTRL P= 0.0001) (Figure 1e). Conversely, Mann–
Whitney testing revealed significantly higher Tb.S value in OP
patients compared with OA and CTRL patients (Figure 1f; OP
0.98±0.114; OA 0.48±0.08 mm; CTRL 0.21± 0.003 mm;
OP versus OA P=0.0040, OP versus CTRL Po0.0001, OA
versus CTRL P= 0.0032).
Bone morphometric analysis allowed us to estimate
trabecular, fat and bone marrow areas (Figures 1g–i). OP
patients showed a lower percentage of trabecular tissue
(29.41%) compared with both the OA and CTRL groups (OA
72.15%; CTRL 87.23%) (OP versus OA P= 0.0021; OP
versus CTRL Po0.0001).
In particular, in OP patients the trabeculae were predomi-
nantly replaced by adipose tissue (OP 70.48% versus CTRL
2.62%), and the bone marrow tissue was significantly reduced
(OP 0.11% versus 10.13 % CTRL; Figures 1g and i).
Conversely, in OA patients, adipose tissue increased much
less (23.40 %) and the residual bone marrow area was
adequately preserved (5.45 %) (Figure 1h).
Immunohistochemical analysis of osteoblast markers.
We analysed the osteoblast differentiation rate in OP, OA and
CTRL patients by immunodetection of specific markers in
cells lining the endostium. Immunohistochemical positivity
was evaluated on digital images (Iscan Coreo, Ventana,
Tucson, AZ, USA) by a semiquantitative approach. We
assigned a score from 0 to 3 according to the number of
positive osteoblasts on the total analysed for runt-related
Table 1 Main characteristics of OP, OA and CTRL patients
OP OA CTRL T-test (Mann–Whitney test)
Age, years 76.65±1.44 74.21±1.26 46.19±2.78 OP versus OA NS (P=0.11); OP versus CTRL *** (Po0.001); OA
versus CTRL *** (Po0.001)
BMI 22.35±1.37 27.06±0.50 — *** (P= 0.0005)
T Score (L1–L4) −2.9±0.13 0.66±0.3 0.85± 0.01 *** (P= 0.0005)
T Score (neck) −2.8±0.18 −0.1±0.12 0.15± 0.08 *** (P= 0.0005)
Creatinine (BUN) (mg/dl) 0.88±0.12 1.70±0.24 — NS (P=0.15)
Azotemia (mg/dl) 50.01±3.5 48.20±4.10 — NS (P=0.70)
Phosphorus (mg/dl) 2.75±0.10 3.20±0.28 — ** (P= 0.0073)
Calcium (mg/dl) 7.99±0.18 9.33±0.14 — NS (P=0.34)
Vit D(25OHD3) (ng/ml) 10.22±2.61 23.63±8.00 — NS (P=0.48)
PTH (pg/ml) 123.10±44.08 92.00±12.08 — NS (P=0.56)
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transcription factor 2 (RUNX2), vitamin D receptor (VDR),
osteoprotegerin (OPG) and PTX3 and positive osteocytes for
sclerostin. For each sample, we evaluated 50 osteoblasts or
osteocytes. The samples containing a number of osteoblasts/
osteocyteso50 were excluded by the analysis. Scoring was
assigned as reported in Table 2.
In the bone biopsies, we observed that the proportion of
RUNX2-positive osteoblasts was not significantly different
between OA and OP patients, while in both cases it was lower
compared with CTRL (CTRL 2.12±0.13; OA 1.16±0.15; OP
0.76±0.13; OP versus OA P=0.4434; OP versus CTRL
Po0.0001; OA versus CTRL Po0.0001; Figure 2).
Similar results were obtained regarding the expression of
VDR (CTRL 1.48± 0.14; OP 0.88± 0.15; OA 1.00±0.11; OP
versus OA P= 0.4974; OP versus CTRL Po0.0001; OA
versusCTRL Po0.0001; Figure 2). Immunohistochemistry for
OPG showed a significant difference among the groups
(Po0.0001). In particular, we observed a relative lower
number of osteoblasts expressing OPG in OP patients
compared with OA and CTRL (OP 0.87± 0.12; OA
1.32± 0.15; CTRL 2.28±0.14; OP versus OA P= 0.0355;
OP versus CTRL Po0.0001; OA versus CTRL Po0.0001;
Figure 3). Also for osteocyte sclerostin expression, we found a
significant group difference (Po0.0001). As expected, there
was a significantly higher relative amount of sclerostin-positive
cells in OP patients compared with OA and CTRL patients (OP
2.24± 0.14; OA 1.36±0.13; CTRL 0.96± 0.09; OP versusOA
Po0.0001; OP versus CTRL Po0.0001; OA versus CTRL
P= 0.0242; Figure 3). These data are in agreement with a
decreased osteoblast differentiation in OP patients.
In vivo PTX3 expression and bone metabolism. Immuno-
histochemical analysis of biopsies revealed that PTX3 was
expressed in human osteoblasts of CTRL. Noteworthy, the
relative number of PTX3-positive osteoblasts was signifi-
cantly lower in OP compared with OA and CTRL patients
Figure 1 Evaluation of bone morphometric parameters. H&E sections of bone head biopsies (a–c, scale bar represents 4 mm.). (a) OP patients showed a remarkable loss of
both trabecular thickness and the number of transversal trabeculae. (b) OA patients display moderate trabecular thinning and decrease of transversal trabeculae, (c) CTRL
patients were characterized by a normal trabecular network. Bone quality parameters evaluated by the BioQuant Osteo software: BV/TV, Tb.Th, and Tb.S (d–f) One-way ANOVA
BV/TV Po0.0001, Tb.Th Po0,0001, Tb.S Po0,0001 (OP n= 25, OA n= 25, CTRL n= 15). Trabecular, fat and bone were calculated by using digital images (g–i). For each
sample, measurements were made at low power magnification
Table 2 Scoring system for immunohistochemical analysis
Score 0 1 2 3
Positive cells ≤2 3≤ x≤12 13≤ x≤22 ≥23
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(OP 1.08±0.14; OA 1.56±0.13; CTRL 2.44± 0.11; OP
versus OA P=0.0140; OP versus CTRL Po0.0001; OA
versus CTRL Po0.0001; Figure 4).
In addition, we plotted PTX3 score and BV/TV or Tb.Th
values for each OP patient. We numbered OP patients in
increasing order of BV/TV or Tb.Th values, respectively.
Interestingly, we found that the few OP patients with relative
elevated number of PTX3-expressing osteoblasts, that is,
score of 2 or 3, showed higher values of BV/TV and Tb.Th
(Figures 4b and c). Altogether, these results suggest a
correlation between bone density and PTX3 expression.
In vitro study of PTX3 expression. We then isolated
osteoblasts from the cancellous bone of OP, OA and CTRL
patients and cultured them in vitro. In all cases, after 4 weeks
of culture, cells became confluent and 495% were immuno-
positive for RUNX2 (Figure 4j). Osteoblasts isolated from
CTRL and OA patients were characterized by the presence of
numerous micro-HA crystals, whereas primary osteoblast
cultures derived from OP showed a poor propensity to form
micro-HA crystals (Figure 4k). Dual-colour immunofluores-
cence reaction showed that PTX3 was expressed by 475%
of RUNX2-positive osteoblasts in primary osteoblast cultures
derived from both OA and CTRL patients (Figures 4j, l and
m). Conversely, we observed rare RUNX2-positive osteo-
blasts expressing PTX3 in cell cultures derived from OP
(Figure 4j). This result was confirmed by western blotting
analysis with PTX3 antibody. Protein extracts of OP, OA and
CTRL osteoblast cultures showed a positive band at about
42 kDa corresponding to the molecular weight of monomeric
PTX3. Noteworthy, the signal was remarkably less intense in
OP than in OA and CTRL samples, corresponding to almost
80% reduction after normalization for housekeeping protein
actin (Figure 4n). At the genomic level, we also demonstrated
the decrease of PTX3 mRNA in osteoblast derived from OP
patients with respect to both osteoblasts of OA and CTRL by
real-time PCR (Figure 4o).
These in vitro results further support the evidence of
impaired PTX3 expression in osteoblasts of OP patients.
In vitro study of PTX3 function. To establish whether PTX3
affects osteoblast behaviour, osteoblasts derived from CTRL
patients cultured for 4 weeks were seeded at a density of
30 ×103 cells/well. At the beginning of culture (T0), 0.1 or
1 μg/ml PTX3 antibody or rabbit IgG at the same concentra-
tions were added to the medium, and cells were cultured for
additional 72 h. Cell proliferation, morphology, micro-HA
crystals and osteoblast characteristics were then evaluated.
The results showed that treatment with anti-PTX3 antibody
significantly inhibited cellular proliferation in a dose-
dependent manner (Figure 5a), without affecting cell viability,
as assessed by nuclear feature (Figure 5g) and trypan blue
Figure 2 Runx2 and VdR expression. Immunohistochemical results were evaluated by a semiquantitative approach assigning a score from 0 to 3 according to the number of
positive osteoblasts (Table 2). (a) OP patients showed low expression of Runx2. (b) Runx2-positive cells were allocated on trabecular surface (arrow). (c) CTRL patients showed
numerous Runx2-positive cells both on trabecular surface and bone marrow. (d) Cytoplasmic expression of VdR in osteoblasts (square) of OP patients. (e) VdR expression in
osteoblasts (square 40 × ; arrow) and bone marrow cells. (f) CTRL patients showed numerous VdR-positive cells both on trabecular surface (square) and bone marrow (arrow).
Scale bar represents 40 μm in all images. (g) Graph shows immunohistochemical results of Runx2 (OP versus OA P= 0.4434; OP versus CTRL Po0.0001; OA versus CTRL
Po0.0001). (h) Graph shows immunohistochemical results of VdR (OP versus OA P= 0.4974; OP versus CTRL Po0.0001; OA versus CTRL Po0.0001). (OP n= 25, OA
n= 25, CTRL n= 15)
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exclusion (data not shown). We assessed these cells for
morphological and metabolic changes indicative of osteoblast
de-differentiation (Figures 5c, d, f and g). Cells cultured in
control conditions showed large and flattened shape, peculiar
of osteoblast phenotype, and positive signal for RUNX2 and
RANKL in 495% of the cells (Figure 5b). Notably, almost all
the osteoblasts cultured in the presence of PTX3 antibody
acquired a spindle shape, resembling fibroblast–mesenchy-
mal cells (Figures 5f and g). In addition, the number of cells
expressing both RANKL and RUNX2 significantly decreased
in conditioned osteoblast cultures compared with controls
(Figure 5b). Osteoblasts cultured in control conditions
aggregated forming numerous cellular clusters (Figures 5c
and d) and showed micron-sized HA crystals both in the
cytoplasmic (nucleation vesicles) and extracellular compart-
ment (Figure 5e) when analysed by SEM and EDX.
Conversely, osteoblasts treated with anti-PTX3 antibody lost
the ability to aggregate in clusters (Figures 5f and g) and
showed rare or absent micro-HA crystal deposition
(Figure 5h). In addition, to further elucidate the effects of
PTX3 on osteoblasts behaviour, we treated osteoblast
primary cultures derived from OP patients with recombinant
human PTX3 (20 ng/ml) for 72 h. As shown in Figure 5, the
effect of exogenous PTX3 induce a significant increase of
both cell proliferation (18.37%) (Figure 5i) and formation of
HA microcrystals (Figure 5j) with respect to cultures treated
with vehicle. Noteworthy, already after 72 h it is possible to
observe the formation of calcified nodules in osteoblast
primary cultures derived from OP patients treated with
recombinant human PTX3.
Discussion
PTX3 is induced by a variety of cytokines in immune cells and
has a non-redundant role in the regulation of inflammation.22 It
acts as an extrinsic onco-suppressor gene in mouse and
human by regulating complement-dependent, macrophage-
sustained, tumor-promoting inflammation.23 Moreover, PTX3
is also produced by several cell types under appropriate
stimuli and, likely owing to its complex quaternary structure, it
is able to interact with several molecules, including growth
factors, extracellular matrix components and fibrinolytic
enzymes, thereby regulating cell proliferation and matrix
remodelling in a variety of tissues.22 It has been recently
shown that human mesenchymal cells derived by bone
marrow express PTX3 when induced to differentiate in vitro
into osteogenic lineage.20 It has been proposed that PTX3
elevation during bone inflammatory conditions promotes
RANKL production and favour osteoclastogenic potential by
osteoblasts, implying its involvement in bone resorption.20 We
now explored the role of PTX3 in bone homeostasis by
studying PTX3 expression in osteoblasts from healthy and OP
patients who experience bone mass loss without apparent
Figure 3 Sclerostin and OPG expression. Immunohistochemistry results were evaluated by a semiquantitative approach assigning a score from 0 to 3 according to the
number of positive osteoblasts for OPG and osteocytes for sclerostin (Table 2). (a) OP patient showed numerous sclerostin-positive osteocytes (square). (b) Trabeculae of a OA
patient characterized by both positive (arrow) and negative osteocytes. (c) Rare sclerostin-positive osteocyte cells in CTRL patients. (d) OP patient with low expression of OPG.
(e) OPG-positive cells localized on the trabecular surface in a OA patient. (f) Numerous OPG positive cells both on the trabecular surface and in bone marrow (arrows) in CTRL
patients. Scale bar represents 40 μm in all images. (g) Graph shows immunohistochemical results of sclerostin (OP versus OA Po0.0001; OP versus CTRL Po0.0001; OA
versus CTRL P= 0.0242). (h) Graph shows immunohistochemical results of OPG (OP versus OA P= 0.355; OP versus CTRL Po0.0001; OA versus CTRL Po0.0001).
(OP n= 25, OA n= 25, CTRL n= 15)
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involvement of inflammatory stimuli. The results show a
positive correlation among PTX3 expression, bone density
and osteoblast proliferation and maturation, indicating that
PTX3 acts as a promoter of bone deposition.
The first aim of this study was to determine whether the
expression of PTX3 in human osteoblasts from OP patients
differed from those from patients affected by OA, that is, of
comparable age (74–76 years) but experiencing bone altera-
tions not linked to bone density loss (surrogate control), and
with those from young (from 18 to 46 years) subjects not
affected by bone diseases (CTRL).
As expected, the mean value of bone morphometric
parameters showed that the bone from OP patients had a
significant reduction of bonemass (BV/TVand Tb.Th). Clinical
analysis excluded the occurrence of osteoporosis in OA and
CTRL patients enrolled. Then immunohistochemical analysis
performed on bone head biopsies of young healthy patients
displayed that, besides hematopoietic bone marrow cells,22 a
high percentage of osteoblasts in the endostium expresses
PTX3. This in vivo observation confirms and extends previous
studies showing that PTX3 expressed by osteoblasts differ-
entiated in vitro from bone marrow mesenchymal cells.20
Interestingly, the comparison of immunohistochemical results
obtained by OP, OA and CTRL showed a close association
between bone health and PTX3. The number of PTX3-
expressing osteoblasts was positively correlated with BV/TV
and Tb.Th values reaching the maximum in the CTRL group.
Noteworthy, the proportion of PTX3-positive osteoblasts
resulted to be significantly lower in OP patients compared
with both young patients and old OA patients. In addition, the
Figure 4 Evaluation of PTX3 in bone head biopsies and osteoblast cell cultures. Immunohistochemical results were evaluated by a semiquantitative approach assigning a
score from 0 to 3 according to the number of positive osteoblasts (Table 2). (a) Graph shows immunohistochemical results of PTX3 (OP versus OA P= 0.0140; OP versus CTRL
Po0.0001; OA versus CTRL Po0.0001). (OP n= 25, OA n= 25, CTRL n= 15) (b and c) Graphs displays the correlation between PTX3 score and BV/TV or Tb.Th values for
each OP patient. OP patients are numbered in increasing order of BV/TVor Tb.Th values, respectively. (f and g) OA patients showed high expression of PTX3 both in osteoblasts
and bone marrow cells. (h and i) CTRL patients showed expression of PTX3 in almost all osteoblasts and bone marrow cells (g, square). Scale bar represents 200 μm for DFH
images and 40 μm for EGI images. (j) Graph shows the results of immunostaining of primary confluent osteoblast cultures (OP n= 3, OA n= 3, CTRL n= 3) (k) Graph shows the
presence of micro-HA crystals in primary confluent osteoblast cultures (OP n= 3, OA n= 3, CTRL n= 3). (l and m) Dual-colour immunostaining for PTX3 (red) and RUNX2
(green) on confluent osteoblasts culture derived from CTRL patients. (l) Images show numerous RUNX2-positive osteoblast expressing PTX3. Scale bar represents 50 μm. (m)
High magnification image of RUNX2-positive osteoblast expressing PTX3. Scale bar represents 10 μm. (n) Representative images of western blotting assay. Western blotting
analysis displayed remarkable difference in PTX3 expression among the groups. Table reported the ratio between the densitometric values of PTX3 and β-catenin for each
experimental group. (OP n= 3, OA n= 3, CTRL n= 3). (o) mRNA expression level of PTX3 relative to GADPH expression in osteoblast primary cultures derived from OP
(0.39± 0.22), OA (0.72± 0.19) and CTRL (1.00± 0.11) patients. (OP n= 3, OA n= 3, CTRL n= 3)
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few OP patients with relative elevated number of PTX3-
expressing osteoblasts also showed higher values of BV/TV
and Tb.Th. Also, preliminary data indicate a positive putative
association between PTX3 serum levels and bone quality in
CD1 mice (data not shown); a significant reduction of BV/TV
and Tb.Th were observed in concomitance with a 15%
decrease of PTX3 serum levels. These results suggested an
active involvement of PTX3 in bone formation.
Ex vivo culture of osteoblasts isolated from the three groups
of patients confirmed in vivo observation. We found that 95%
of the cells were immunopositive for the osteoblast lineage
master gene RUNX2 regardless of their patient origin, but OP
primary osteoblast cultures showed deep difference with the
other two groups in PTX3 co-expression. Of all the RUNX2-
positive cells,475% was also positive for PTX3 in CTRL and
OA primary osteoblast cultures while the number dropped to
5–10% in OP osteoblast cultures. Accordingly, western
blotting analysis showed 80% reduction of PTX3 in the cell
culture extracts of OP compared with CTRL and OA samples.
The evidence that the deficiency of PTX3 production is
maintained by OP-derived osteoblasts when cultured in vitro
suggests that PTX3 gene is not negatively affected by
environmental factors but rather that an appropriate positive
signal is missing or that the PTX3 promoter is stably silenced
by epigenetic mechanisms, as recently demonstrated in
human cancers.24 That PTX3 is positively involved in bone
metabolism is further supported by the evidence that cell
cultures derived from OP patients displayed a poor propensity
to produce mineralized matrix as demonstrated by rare
presence of micro-HA crystals. Moreover, the treatment of
human osteoblast primary cultures derived from CTRL
patients with anti-PTX3 antibody induced considerable
changes in osteoblast behaviour. Specifically, they lost the
morphological and molecular features typical of mature
osteoblasts, acquiring fibroblast-like shape and drastically
decreasing RANKL and RUNX2 expression. Notably, the
inhibition of PTX3 negatively affected osteoblast’s proliferation
and their ability to form both cellular clusters and micro-HA
crystals. In addition, we reported the effects of exogenous
PTX3 on osteoblast primary cultures derived from OP
patients. Our data clearly demonstrated the ability to PTX3
to induce an increase of both cell proliferation and HA
Figure 5 Effects of anti-PTX3 antibody on human osteoblast primary cultures. (a) Graph displays the percentage of proliferating osteoblasts in treated and control primary
cultures (Ig 0.1 μg/ml versus PTX3 0.1 μg/ml Po0.0001; Ig 1 μg/ml versus PTX3 1 μg/ml Po0.001). (b) Table showed the main characteristics of primary osteoblast cultures
after 72 h of treatment with PTX3 antibody (cellular cluster IgG 0.1 μg/ml versus PTX3 0.1 μg/ml *P= 0.0048; IgG 1 μg/ml versus PTX3 1 μg/ml P= 0.0501; HA microcrystals
IgG 0.1 μg/ml versus PTX3 0.1 μg/ml **P= 0.0017; IgG 1 μg/ml versus PTX3 1 μg/ml **P= 0.0035; RANKL IgG 0.1 μg/ml versus PTX3 0.1 μg/ml *P= 0.0354; IgG 1 μg/ml
versus PTX3 1 μg/ml *P= 0.0317; RUNX2 IgG 0.1 μg/ml versus PTX3 0.1 μg/ml *P= 0.0330; IgG 1 μg/ml versus PTX3 1 μg/ml *P= 0.0418). Well-differentiated osteoblasts
forming numerous cellular cluster (arrows) in control cultures (1 μg/ml rabbit IgG; 72 h). Scale bar represents 200 μm for panel (c) image and 100 μm for panel (d) image. (e)
SEM-EDX analysis showed the presence of well-differentiated osteoblast and micro-HA calcifications (arrows) in cell cultures treated with 1 μg/ml rabbit IgG (72 h). Scale bar
represents 30 μm. (f and g) After 72 h, the treatment with 1 μg/ml of anti-PTX3 antibody induced a strong reduction of osteoblasts size and the appearance of cells with
fibroblast–mesenchymal characteristics. Scale bar represents 200 μm for panel (f) image and 100 μm for panel (g) image. (h) Electron micrograph shows ultrastructural
characteristics of fibroblast–mesenchymal-like cells. Scale bar represents 30 μm. (i) rhPTX3 induce a significant increase of cell proliferation in primary osteoblast cultures
derived from OP patients (P= 0.0023) (j) rhPTX3 induce a significant increase of HA crystal formation in primary osteoblast cultures derived from OP patients (Po0.001)
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microcrystal formation in osteoblasts characterized by no/low
expression of PTX3. These results suggest a central role of
PTX3 in osteoblast proliferation, differentiation and function. In
this context, FGF2 could be a key mediator of the relationship
between bone metabolism and PTX3. It is known that PTX3
contains two FGF2-binding sites and sequesters this growth
factor thereby inhibiting its action on target cells.25 This
interaction can modulate the capability of FGF2 to interfere
with osteoblast activity. Indeed, although FGF2 is generally
considered to favour bone deposition, it exerts differentiation-
stage-specific effects on osteoblasts.26 Thus, the ability of
PTX3 to sequester FGF2 via its N-terminal extension can
influence the osteoblastogenesis by regulating the activity of
FGF2.
The correlation between osteoblast PTX3 deficiency and
low bone density reported here in humans well matches with
bone structure deficiency and impaired fracture healing
observed in the animal model of PTX3 null mice.21
The requirement of fine control of PTX3 expression for
maintaining the bone in good health is also strengthened by
the studies performed in conditions mimicking in vivo and
in vitro acute inflammation.20 In such inflamed situations,
cytokines induced PTX3 overexpression by osteoblasts,
which in turn increased their osteoclastogenic potential by
elevating RANKL production. Altogether, these results allow to
hypothesize an opposite effect of PTX3 in the delicate balance
of bone remodelling depending on health conditions. In
physiological conditions, the expression of PTX3 would
stimulate osteoblast differentiation by bone marrow mesench-
ymal stem cells. On the other hand, a decreased PTX3
production, as that observed in OP patients, could result in
inadequate bone formation and an excessive PTX3 elevation
in inflammatory conditions, such as in rheumatoid arthritis,
could promote bone resorption, in both cases leading to bone
mass loss.
Limits of the study. The evaluation of PTX3 was performed
using a semiquantitative approach (immunohistochemistry),
as protein or mRNA extraction is difficult to perform on bone
biopsies. In addition, it is not always possible to obtain
suitable material from clinical sources. To corroborate our
results, western blotting analysis was performed on primary
osteoblast cultures derived from OP, OA and CTRL patients.
In our laboratory, blood serum concentration of creatinine,
nitrogen (BUN), phosphorus, calcium, Vit D (25OHD3) and
intact parathyroid hormone (PTH) were not assessed in
patients undergoing hip arthroplasty for high-energy hip
fractures. Nevertheless, the bone quality of all these patients
was evaluated by histomorphometric analysis (Figure 2).
Unfortunately, it is very difficult to collect bone head biopsies
of patients aged470 years without OP or OAwho underwent
hip arthroplasty for high-energy hip fractures. However, the
results demonstrated that OA patients were good surrogate
controls in this study, showing several similarities with
younger patients.
Conclusions
The identification of new determinants of bone loss in
osteoporosis is a field in constant development. This study
suggests an important role of PTX3 in normal bone home-
ostasis showing its involvement in osteoblast proliferation,
differentiation and function. Its impaired expression by
osteoblast cells in OP patients strongly support the hypoth-
esis, that PTX3 is a novel regulator of bone metabolism with
prominent effects on cellular processes that are essential for
normal bone physiology. Further studies are needed to
elucidate the molecular mechanisms through which PTX3
regulates the activities of osteoblasts.
Materials and Methods
All experiments described in the present study were approved by the ethics
committee of ‘Policlinico Tor Vergata’ (approval reference number 85/12). All
experimental procedures were carried out according to The Code of Ethics of the
World Medical Association (Declaration of Helsinki). Informed consent was obtained
from all patients prior to surgery. Specimens were handled and carried out in
accordance with the approved guidelines.
Patients. We enrolled 65 patients who underwent hip surgery in the Orthopaedic
Department of ‘Tor Vergata’ University Hospital in the period June 2014–February
2015. We enrolled 25 consecutive patients who underwent hip arthroplasty for
medial hip fractures for low-energy trauma (18 women and 7 men; 76.65± 1.44
years), and 25 consecutive patients who underwent hip arthroplasty for OA (15
women and 10 men; 74.21± 1.26 years). Moreover, we enrolled 15 patients
(7 women and 8 men; 46.19± 2.78 years) who underwent hip arthroplasty for high-
energy hip fractures (control group) (Table 1).
Exclusion criteria were history of cancer, myopathies or other neuromuscular
diseases or chronic administration of corticosteroid for autoimmune diseases
(41 month), diabetes, alcohol abuse and HBV, HCV or HIV infections.
Bone mineral density evaluation (DXA). DXA was performed with a
Lunar DXA apparatus (GE Healthcare, Madison, WI, USA). Lumbar spine (L1–L4)
and femoral (neck and total) scans were performed, and bone mineral density
(BMD) was measured according to the manufacturer’s recommendations.27 Dual-
energy X-ray absorptiometry measures BMD (in grams per square centimetre), with
a coefficient of variation of 0.7%. For patients with fragility fractures, BMD was
measured on the uninjured limb. For all the other patients, measurements were
performed on the non-dominant side, with the participants supine on an examination
table with their limbs slightly abducted.28 DXA exam was performed 1 day before
surgery for OA patients and 1 month after surgery for OP and control patients
(CTRL). The results were expressed as T-scores.
Radiographic analysis. Anteroposterior radiographs of the pelvis of all
groups were obtained using a standard, validated protocol.29 Two orthopaedists
independently assessed all radiographs using the K–L radiographic atlas.30 Patients
with a grade of K–L≥ 2 were considered osteoarthritic.
Blood tests. Blood serum concentration of creatinine, nitrogen (BUN),
phosphorus, calcium, Vit D (25OHD3) and intact PTH were assessed.
Sampling. At surgery, the femoral head was removed to implant prosthesis.
Bone samples were taken for histological analysis, excluding areas with
macroscopic alterations of trabecular bone such as necrotic areas.
Histology. Bone biopsies of the femoral head were fixed in 4% paraformalde-
hyde for 24 h and paraffin embedded without decalcification.31 From each patient,
we obtained two paraffin blocks. Undecalcified tissues were cut by a tungsten
carbide knife; 3 μm-thick sections were stained using H&E.
Histomorphometric analysis. Ten microscopic images, randomly selected,
were evaluated for each biopsy sample. Images were acquired at × 40 magnification
using a Nikon Eclipse E600 light microscope connected to a Nikon digital camera
(Nikon Corp, Japan) and saved at a resolution of 1280 × 1024 pixels. Image analysis
was performed using a BioQuant Osteo software (version7.20.10; BIOQUANT
Image Analysis Corporation, Nashville, TN, USA) according to the manufacturer’s
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instructions.32 The following parameters: BV/TV, Tb.Th, and Tb.S, were evaluated
according to Dempster et al.33
Moreover, H&E slides were analysed using the Viewing software (Ventana,
Tucson, AZ, USA) to evaluate bone tissue composition (trabecular, bone marrow
and fat).
Immunohistochemistry. RUNX2, VdR, OPG, sclerostin and PTX3 expression
were assessed in femoral head biopsies by immunohistochemistry. Briefly, 3 μm-thick
sections were pretreated with EDTA citrate pH 7.8 for 30 min at 95 °C and then
incubated with mouse monoclonal anti-RUNX2 antibody for 60 min (1 μg/ml, clone
EPR14334, AbCam, Cambridge, UK), rabbit monoclonal Anti-VDR for 60min (1 μg/ml,
clone SP141, Spring Bioscience, CA, USA), rabbit polyclonal anti-sclerostin antibody
for 60 min (1 μg/ml, clone NA, AbCam), mouse monoclonal Anti-OPG for 60 min
(1 μg/ml, clone 98A1071, Novus Biologicals, Littleton, CO, USA). For PTX3
evaluation, sections were pretreated with citrate pH 6 for 30 min at 95 °C and then
incubated with rat monoclonal anti-PTX3 for 120 min (2 μg/ml, clone MNB1, AbCam).
Washings were performed with PBS/Tween20 pH 7.6 (UCS Diagnostic, Rome, Italy);
reactions were revealed by horseradish peroxidase (HRP)-3,3' diaminobenzidine
(DAB) Detection Kit (UCS Diagnostic). To assess the background of immunostaining,
we included a negative control for each reaction by incubating the sections with
secondary antibodies (HRP) and a detection system (DAB).
Human osteoblast primary cell cultures: Primary cultures of osteoblasts
were obtained from the cancellous bone of: patients with high-energy femoral
fracture (CTRL, Caucasian, 18 years), patients affected by osteoporosis (OP,
Caucasian, 71 years), and patients affected by osteoarthrosis (AO, Caucasian, 72
years). The samples were dissected and treated to obtain a homogeneous
population of osteoblasts. Briefly, after dissection, trabecular bone fragments were
repeatedly washed in PBS. Then bone fragments were briefly incubated at 37 °C
with 1 mg/ml Trypsin from porcine pancreas ≥ 60 /mg (SERVA Electrophoresis
GmbH, Heidelberg, Germany) diluted in DPBS. After washing, bone fragments were
subjected to repeated digestions with 2.5 mg/ml Collagenase NB 4G Proved grade
≥ 0.18 U/mg (SERVA Electrophoresis GmbH) diluted in DPBS with calcium and
magnesium. Supernatant were collected and centrifuged at 310 RCF for 5 min. Cell
pellets were resuspended in DMEM with 15% FBS, seeded into a 24-well plate and
incubated at 37 °C, 5% CO2 until reaching confluence (about 4 weeks). Medium
was changed twice a week. Osteoblasts were characterized by alkaline
phosphatase test and immunostained for RUNX2 and RANKL.
Immunostaining of primary cell cultures: Expression of RUNX2 and PTX3
was simultaneously evaluated by dual-colour immunofluorescence in confluent
CTRL, OP and OA primary osteoblast cultures. Briefly, after fixation in PFA 4% for
30 min, cell cultures were pretreated with EDTA citrate pH 7.8 for 5 min at 95 °C
and incubated with mouse monoclonal anti-RUNX2 antibody for 30 min (1 μg/ml,
clone EPR14334, AbCam). Reaction with anti-Runx2 was revealed by using FITC-
conjugated anti-mouse antibody. Afterwards, cell cultures were incubated with rat
monoclonal anti-PTX3 (2 μg/ml, clone MNB1, AbCam) for 30 min. Reaction with
anti-PTX3 was revealed by using Texas Red-conjugated anti-rat antibody. Washing
was performed with PBS/Tween 20 pH 7.6 (UCS Diagnostic).
Western blotting analysis. To detect PTX3 in osteoblast primary cultures
derived by OP (n= 3), OA (n= 3) and CTRL (n= 3) patients, we performed a
western blotting analysis. Cell proteins extracted by using RIPA buffer were
separated by 4–15% precast SDS-PAGE (Bio-Rad, Hercules, CA, USA) under
reduced conditions. Protein concentration was determined using the Pierce BCA
Protein Assay Kit (Thermo Scientific, Vilnius, Litheania). Equal amounts of protein
(20 μg) were resolved on 8–16 % SDS-PAGE and transferred to nitrocellulose
membrane. Then membranes were incubated with a rat monoclonal antibody
against human PTX3 (1 μg/ml, clone MNB1, AbCam) and successively with anti-rat
IgG coupled to HRP. Inmunoreactive electrophoretic bands were detected by
enhanced chemiluminiscence ECL Advance, Amersham (GE Healthcare Life
Sciences, Little Chalfont, Buckinghamshire, UK) using a VersaDoc 5000 Imager
(Bio-Rad) and quantified by the Quantity One software (Bio-Rad). Relative amounts
of PTX3 were normalized for the corresponding β-actin values from cell lysates.
Real-time PCR. RNA was isolated from cells by using Qiazol reagent (Qiagen,
Hilden, Germany), and 1 mg of RNA was reverse-transcribed into cDNA by using
the RevertiAid First Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative
real-time PCR was performed by using a Power SYBR Green 1-Step Kit and the
ABI 7000 Real Time PCR System (Applied Biosystems, Carlsbad, CA, USA)
according to the manufacturer’s instructions.34 The sequences of the primers
used were: PTX3, 5′-TTTTGGAAGCGTGCATCCTGT-3′ (sense) and 5′-
CACCACCAACACTAGGGACTG-3′ (antisense).
Osteoblast primary cultures conditioned with anti-PTX3 anti-
body. To evaluate the role of PTX3 in osteoblast activity, we treated primary
osteoblast cultures from CTRL patient with anti-PTX3 antibody (clone MNB1,
AbCam). In detail, cells from the first or second passage were seeded into a 24-well
plate at a density of 30 × 103 cells/well. Successively, human osteoblast cells were
treated with: (a) Rabbit anti-mouse IgG 0,1 μg/ml (CTRL), (b) Rabbit anti-mouse
IgG 1 μg/ml (CTRL), (c) mouse monoclonal anti-PTX3 (clone MNB1) 0,1 μg/ml, and
(d) mouse monoclonal anti-PTX3 (clone MNB1) 1 μg/ml. Cell proliferation,
morphology, micro-HA crystals and osteoblast characteristics were evaluated at
time 0, 6, 24, 48 and 72 h. Cell proliferation was investigated by both counting the
number of cells for each time point and bromodeoxyuridine Incorporation Assay
performed at time 0 and after 72 h. Morphology was studied by both toluidine blue
staining and SEM analysis. Identification of micro-HA crystals was performed by
SEM-Energy Dispersive X-ray (EDX) microanalysis, whereas osteoblast markers
were studied by immunofluorescence for RUNX2 (1 μg/ml, clone EPR14334,
AbCam) and RANKL (mouse monoclonal anti-RANKL, 1 μg/ml, clone 12A380).
Osteoblast primary cultures of OP conditioned with recombinant
human PTX3. To further elucidate the functions of PTX3 on osteoblast
behaviour, we examined the effects of exogenous PTX3 on osteoblasts derived from
OP patients by culturing it with 20 ng/ml of recombinant human PTX3 for 72 h. In
detail, cells from the first or second passage were seeded into a 24-well plate at a
density of 30 × 103 cells/well. Successively, human osteoblast cells were treated
with: (a) 20 ng/ml recombinant human PTX3 and (b) Vehicle (equal amount of PBS).
Cell proliferation was investigated by bromodeoxyuridine Incorporation Assay
performed at time 0 and after 72 h. Identification of micro-HA crystals was performed
by SEM-EDX microanalysis.
Statistical analysis. All statistical analyses were performed using the
GraphPad Prism 5 Software (GraphPad Prism, La Jolla, CA, USA).
Clinical data were analysed by Mann–Whitney test; immunohistochemical and
morphometric parameters were analysed by one-way ANOVA and Mann–Whitney
test. Cell growth, cellular clusters, micro-HA calcifications and both RUNX2 and
RANKL expression of primary osteoblasts cultures was analysed by one-way ANOVA
and t-test.
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